CNBC Investing Club: Cramer’s Morning Take on Alphabet 3/13/26

SPEAKER_1 (0:00)

Thy ticket, Lady Jennifer of Coolidge.

Jim Cramer (0:03)

Well, many thanks, good sir.

SPEAKER_1 (0:05)

Heareth my Discover card.

SPEAKER_3 (0:08)

They accept Discover at Renaissance Fairs? Yeah, they do here.

Jim Cramer (0:12)

Discover is accepted at the places I love to shop. Getteth with the times.

Jeff Marks (0:17)

With the times?

SPEAKER_5 (0:18)

You're playing the lute. Yeah, and it sounds pretty good, right?

SPEAKER_3 (0:23)

Discover is accepted at 99% of places that take credit cards nationwide. Based on the February 2025 Nielsen Report.

SPEAKER_5 (0:30)

This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com/marketupdatepodcast or find Schwab Market Update wherever you get your podcasts.

Jim Cramer (1:01)

Jim Cramer here to share a short preview of my take on the market from today's members-only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 1020 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take. I've got to tell you, Jeff, that it is a little lower than it was, but you know what I think. I think the oscillator at minus 7.5 forces our hand to put money to work.

Jeff Marks (1:38)

We did that this morning with Alphabet, one of the stocks we laid out yesterday on a shopping list if we weren't restricted from trading so many stocks, not restricted today. But I'm glad you mentioned the oscillator, because it's not every day we see it this low. Minus 10, by the way, you have to go back to Liberation Day last year.

Jim Cramer (1:59)

And we're close to that.

Jeff Marks (2:00)

September 2022, which was great times to buy.

Jim Cramer (2:04)

These are what my late friend Mark Haynes would call exquisite moments, exquisite moments to buy. It doesn't feel good. I mean, you're buying ahead of a weekend. That's been wrong.

Jeff Marks (2:16)

Yeah.

Jim Cramer (2:17)

I don't care. I am making a statement as we are making a statement that some of our stocks are at prices that are bargains.

Jeff Marks (2:25)

And what does the oscillator tell us that there's been a lot of selling pressure and that we could get a big rally on any bit of good news. So you still need to see the good news, right? Well, but we need to see oil come down.

Jim Cramer (2:37)

Well, oil is coming down today.

Jeff Marks (2:39)

Down today.

Jim Cramer (2:41)

Is it? Why is it down? Well, even though Hagseth and the president are saying horrible things, we have countries talking to the radios with the idea that they can get oil through.

Jeff Marks (2:54)

FT reporting. France and Italy open to talks.

Jim Cramer (2:56)

Cramer oil was fungible. So if you send something through, do they follow it to Switzerland? I don't know. If oil goes through, then the world benefits. So I think that maybe you take off the table the embargo if a couple countries get through it. And then the President of the United States can say, listen, guys, if you go nuclear, we are going to crush you. We will just bury Tehran. I mean, some horrible thing. And I don't want it. I don't want any of this stuff. But they like to say, I mean, Hicks has said that human life basically seems to not value it. I mean, I didn't know how else to view what his comments were.

Jeff Marks (3:34)

We got the alphabet chart up here. Down 2% for the year. It has pulled back since the high.

Jim Cramer (3:41)

We finally get it. I can't believe we got it. It's so great we got it.

SPEAKER_1 (3:45)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_3 (4:17)

Snoring? Gasping during sleep? Feeling fatigued? Wake up to ZepBound Terzepatide, the first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea, OSA and adults with obesity. ZepBound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea, OSA and obesity to improve their OSA. ZepBound should be used with a reduced calorie diet and increased physical activity. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5 or 15 milligram injection. ZepBound contains Terzepatide and should not be used with other Terzepatide containing products or any GLP-1 receptor agonist medicines. It is not known if ZepBound is safe and effective for use in children. Do not share needles or pens or reuse needles. Don't take ZepBound if allergic to it or if you or someone in your family had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 Tell your doctor if you get a lump or swelling in your neck. Stop ZepBound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes, depression or suicidal thoughts before scheduled procedures with anesthesia. If you're nursing, pregnant, planned to be or taking birth control pills. Taking ZepBound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor. Call 1-800-545-5979 or visit zepbound.lily.com. ZepBound and its delivery device base in QuickPin are registered trademarks owned or licensed by Eli Lilly & Company, its subsidiaries or affiliates.